WB result of Phospho-EGF Receptor (Tyr1068) Recombinant Rabbit mAb
Blocking/Diluting buffer and concentration: 5% NFDM/TBST
Primary antibody incubation conditions: overnight at 4°C
Primary antibody: Phospho-EGF Receptor (Tyr1068) Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: untreated BxPC-3 whole cell lysate 20 µg
Lane 2: BxPC-3 treated with 100 ng/ml hEGF for 5 minutes whole cell lysate 20 µg
Lane 3: untreated A431 whole cell lysate 20 µg
Lane 4: A431 starve overnight, then treated with 100 ng/ml hEGF for 5 minutes whole cell lysate 20 µg
Secondary antibody: Goat Anti- rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 134 kDa
Observed MW: 180 kDa
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | Phospho-EGF Receptor (Tyr1068) |
| Synonyms | Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1 |
| Location | Cell membrane |
| Accession | P00533 |
| Clone Number | S-4267 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu, Ms, Rt |
| Positive Sample | BxPC-3 (treated with 100 ng/ml hEGF for 5 minutes), A431 (starve overnight, then treated with 100 ng/ml hEGF for 5 minutes) |
| Predicted Reactivity | Ms, Rt, Mk |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu,Ms,Rt |
Background
Phospho-EGF Receptor (Tyr1068) is one of the most critical autophosphorylation sites signifying EGFR tyrosine kinase activation. Its phosphorylation is strictly dependent on ligand-induced receptor dimerization and the subsequent conformational activation of the intracellular kinase domain. Upon phosphorylation, Tyr1068 functions as a high-affinity docking site that directly recruits the adaptor protein GRB2, thereby cascading downstream activation of the MAPK/ERK proliferative signaling and PI3K/AKT survival pathways via the SOS/RAS axis. This site exhibits precise functional分工 with other C-terminal domain residues—Y1045 (c-Cbl binding mediating degradation), Y992 (PLCγ binding), and Y1173 (Shc scaffold binding)—with Y1068 being specifically dedicated to GRB2-mediated pro-proliferative signal input. Its phosphorylation level is subject to stringent subcellular spatial regulation: it is directly dephosphorylated at the plasma membrane by receptor-type phosphatases such as PTPRJ to limit signal intensity, and upon internalization to the endoplasmic reticulum, it is inactivated by PTPN2, forming a spatially dependent negative feedback braking mechanism. In terms of clinical translation, pY1068 has transcended its role as a classic marker of EGFR activation. Large-scale studies in advanced non-small cell lung cancer (NSCLC) have demonstrated that positivity for this phosphorylation site serves as an independent predictive biomarker for significant progression-free survival (PFS) benefit from gefitinib or erlotinib treatment in EGFR wild-type patients (median PFS 4.2 months vs. 1.2 months).
Picture
Picture
Western Blot
